The rising demand for GLP-1 medications — widely recognized for their effectiveness in weight management and chronic disease prevention — has created a significant coverage gap in Medicare.
HR Review
July 2026
Check out the July 2026 edition of our monthly Newsletter. This newsletter is brought to you by eBen and Risk Strategies.
ACA Employer Shared Responsibility Penalties Released for 2027
Employers sponsoring benefit plans subject to ERISA should take note of the upcoming Form 5500 filing deadline on July 31, 2026 for calendar year plans.
The Rise of In-Network Virtual Providers and Clinics
Learn what employers can do to take full advantage of the services delivered through virtual care from in-network providers and clinics.
Understanding Health Insurance Preauthorization
Learn how employers can play an active role in working with their insurance carriers and TPAs to ensure their preauthorization processes are streamlined.
How TrumpRx Works With Medicare Prescription
Drug Coverage
Learn how programs like TrumpRx help beneficiaries lower their out-of-pocket expenses and how to make informed decisions about your pharmacy benefits.
CMS Finalizes Two Significant Medicare Part D Creditable Coverage Changes for 2027
On April 2, 2026, CMS released a final rule for plan years beginning in calendar year 2027 impacting the Medicare Part D prescription drug benefit program.
2026 Compliance Reminder:
Upcoming Form 5500 Deadline for Calendar Year Plans
Employers sponsoring benefit plans subject to ERISA should take note of the upcoming Form 5500 filing deadline on July 31, 2026 for calendar year plans.
2026 Compliance Reminder: Upcoming Form 5500 Deadline for
Calendar Year Plans
Employers sponsoring benefit plans subject to ERISA should take note of the upcoming Form 5500 filing deadline on July 31, 2026 for calendar year plans.
Capital Motivated Reinsurance for Health Plan CFOs: A Flexible Capital Strategy
Explore how capital motivated reinsurance helps health plan CFOs improve capital efficiency, unlock surplus, and support growth without debt or dilution.












